These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 10925090)

  • 1. Can prostate epithelial content predict response to hormonal treatment of patients with benign prostatic hyperplasia?
    Eri LM; Svindland A
    Urology; 2000 Aug; 56(2):261-5. PubMed ID: 10925090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Morphometry of benign prostatic hyperplasia during androgen suppressive therapy. Relationships among epithelial content, PSA density, and clinical outcome.
    Svindland A; Eri LM; Tveter KJ
    Scand J Urol Nephrol Suppl; 1996; 179():113-7. PubMed ID: 8908676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective, placebo-controlled study of the antiandrogen Casodex as treatment for patients with benign prostatic hyperplasia.
    Eri LM; Tveter KJ
    J Urol; 1993 Jul; 150(1):90-4. PubMed ID: 7685428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of bicalutamide on prostate histology.
    Eri LM; Svindland A; Tveter KJ
    Prostate; 2001 Mar; 46(4):275-80. PubMed ID: 11241549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of benign prostatic hyperplasia by androgen deprivation: effects on prostate size and urodynamic parameters.
    Bosch RJ; Griffiths DJ; Blom JH; Schroeder FH
    J Urol; 1989 Jan; 141(1):68-72. PubMed ID: 2462067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravesical prostatic protrusion can predict therapeutic response to silodosin in male patients with lower urinary tract symptoms.
    Matsukawa Y; Ishida S; Majima T; Funahashi Y; Sassa N; Kato M; Yoshino Y; Gotoh M
    Int J Urol; 2017 Jun; 24(6):454-459. PubMed ID: 28370376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relative proportion of stromal and epithelial hyperplasia is related to the development of symptomatic benign prostate hyperplasia.
    Shapiro E; Becich MJ; Hartanto V; Lepor H
    J Urol; 1992 May; 147(5):1293-7. PubMed ID: 1373778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide.
    Axcrona K; Aaltomaa S; da Silva CM; Ozen H; Damber JE; Tankó LB; Colli E; Klarskov P
    BJU Int; 2012 Dec; 110(11):1721-8. PubMed ID: 22500884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective, placebo-controlled study of the luteinizing hormone-releasing hormone agonist leuprolide as treatment for patients with benign prostatic hyperplasia.
    Eri LM; Tveter KJ
    J Urol; 1993 Aug; 150(2 Pt 1):359-64. PubMed ID: 7686981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia.
    Peters CA; Walsh PC
    N Engl J Med; 1987 Sep; 317(10):599-604. PubMed ID: 2441256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist greatly augments benign prostatic hyperplasia shrinkage.
    Rick FG; Szalontay L; Schally AV; Block NL; Nadji M; Szepeshazi K; Vidaurre I; Zarandi M; Kovacs M; Rekasi Z
    J Urol; 2012 Apr; 187(4):1498-504. PubMed ID: 22341819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of bicalutamide and leuprolide on prostate-specific antigen (PSA), acid phosphatase (ACP) and prostatic acid phosphatase (PAP) in men with benign prostatic hyperplasia (BPH).
    Eri LM; Tveter KJ
    Prostate Cancer Prostatic Dis; 2001; 4(3):173-177. PubMed ID: 12497037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters.
    Yannucci J; Manola J; Garnick MB; Bhat G; Bubley GJ
    J Urol; 2006 Aug; 176(2):520-5. PubMed ID: 16813881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The limited significance of a longer duration of neoadjuvant hormonal therapy prior to radical prostatectomy for high-risk prostate cancer in Japanese men.
    Miyake H; Sakai I; Inoue TA; Hara I; Fujisawa M
    Urol Int; 2006; 77(2):122-6. PubMed ID: 16888415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of intravesical prostatic protrusion and resistive index is useful to predict bladder outlet obstruction in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
    Suzuki T; Otsuka A; Ozono S
    Int J Urol; 2016 Nov; 23(11):929-933. PubMed ID: 27545297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of neoadjuvant bicalutamide and dutasteride as a cytoreductive regimen before prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen ZA; Kurko B
    Urology; 2006 Jul; 68(1):116-20. PubMed ID: 16844453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effectiveness of luteinizing hormone-releasing hormone agonist or antiandrogen monotherapy in elderly men with localized prostate cancer (T1-2): a retrospective study.
    Raina R; Pahalajani G; Agarwal A; Zippe C
    Asian J Androl; 2007 Mar; 9(2):253-8. PubMed ID: 17334592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate-specific antigen-all that rises is not refractory.
    Hintz BL; Van Nieuwenhuize A; Kagan AR
    Urology; 2001 May; 57(5):975. PubMed ID: 11337308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of goserelin and leuprolide in combined androgen blockade therapy.
    Sarosdy MF; Schellhammer PF; Sharifi R; Block NL; Soloway MS; Venner PM; Patterson AL; Vogelzang NJ; Chodak GW; Klein EA; Schellenger JJ; Kolvenbag GJ
    Urology; 1998 Jul; 52(1):82-8. PubMed ID: 9671875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.